PT  - JOURNAL ARTICLE
AU  - D P Brooks
AU  - L C Contino
AU  - W Trizna
AU  - R M Edwards
AU  - E H Ohlstein
AU  - H A Solleveld
TI  - Effect of enalapril or the thromboxane receptor antagonist, daltroban, in rats with subtotal renal ablation.
DP  - 1990 Apr 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 119--123
VI  - 253
IP  - 1
4099  - http://jpet.aspetjournals.org/content/253/1/119.short
4100  - http://jpet.aspetjournals.org/content/253/1/119.full
SO  - J Pharmacol Exp Ther1990 Apr 01; 253
AB  - There is evidence to suggest that thromboxane synthesis inhibition will attenuate the hypertension and proteinuria associated with subtotal renal ablation. In the present study, the thromboxane receptor antagonist, daltroban, (30 mg/kg/day i.p.) or vehicle was administered to rats for 3 weeks starting 2 weeks after partial renal ablation (right uninephrectomy and ligation of approximately two-thirds of the blood supply to the left kidney). Renal ablation was associated with proteinuria and increased systolic blood pressure. Neither the proteinuria nor the hypertension was affected by daltroban administration. Histological examination of the remaining kidney demonstrated no beneficial effect of daltroban. In a second study, it was determined that, 2 weeks after renal ablation, urinary thromboxane excretion was significantly increased, and subsequent administration of daltroban for 2 weeks resulted in significant blockade of the effects of the thromboxane mimetic, U46619. In a third study, enalapril (50 mg/l in the drinking water) resulted in a significant attenuation of the proteinuria, hypertension and glomerular lesions associated with partial renal ablation. The data indicate that enalapril, but not daltroban, protects against the development of renal disease associated with reduced renal mass.